You should follow a healthy lifestyle (diet and exercise) in order to maintain a stable weight after treatment
Age-related changes in kidney function can also slow clearance, particularly in patients over 65, potentially requiring dose adjustments or longer intervals between administrations
Only Part D drugs will qualify for this type of fill
GLP-1, secreted by the intestine, brainstem, and pancreas, also exerts appetite-suppressing and gastric emptying-delaying effects on the hypothalamus
For many individuals struggling with obesity, this surgical intervention offers a promising solution to achieve long-term weight loss and improve overall health
When initiating GLP-1 therapy in conjunction with insulin or a sulfonylurea, providers may consider proactive dose reductions of those agents to avoid potential hypoglycemia